Novo Nordisk A/S (ETR:NOV)

Market Cap	192.30B
Revenue (ttm)	41.82B
Net Income (ttm)	14.89B
Shares Out	n/a
EPS (ttm)	3.35
PE Ratio	12.92
Forward PE	12.03
Dividend	1.53 (3.65%)
Ex-Dividend Date	Mar 28, 2025

Volume	1,277,133
Average Volume	756,832
Open	42.54
Previous Close	41.86
Day's Range	42.14 - 43.98
52-Week Range	38.51 - 126.34
Beta	0.27
RSI	34.06
Earnings Date	Aug 6, 2025

About United States Steel

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 77,349
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: NOV

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.